About Us

Company Overview & Vision


BioEclipse Therapeutics™ is a clinical-stage oncology company that uses its proprietary platform technology to develop the next generation of immuno-oncology therapeutics.


Foundationally, we have harnessed a refined understanding of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors. In response, BioEclipse Therapeutics pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells. The result of this combination is a multi-mechanistic, targeted treatment that we believe will not only eradicate cancer cells, but also protect the patient from relapse and recurrence, through a durable immune response that prevents the development of new cancers, even in the face of new challenges from disease.

abstract lab equip
Clark center atrium BW

Corporate History


BioEclipse Therapeutics was founded as ConcentRx Inc. and was renamed in 2017, concomitant with launching our clinical strategy, with new funding and the build out of an experienced executive team and an independent Board of Directors. Our Board of Directors is now made up of life science company investors, and biopharmaceutical executives with product development and commercial expertise.


BioEclipse Therapeutics will enter Phase 1 clinical trials with an intravenously-delivered, targeted biotherapy against refractory solid tumors. Our first-in-class immunotherapy, CRX100, delivers potentially curative treatments to patients over a broad range of tumor types, including hard-to-treat cancers that many consider untreatable. The first product from our platform, CRX100, is made up of two components, both of which have been tested independently in clinical trials. We are entering an open Phase 1 clinical trial in six tumor types.



Lead Therapeutic Candidate CRX100


A New Class in Combination Immunotherapy Cancer Treatments


  • Activated innate immune cells protect and deliver an oncolytic virus to the target
  • Intravenous, not intra-tumoral delivery
  • Safety and tolerability of each therapeutic component confirmed in humans
  • Viral particles are delivered directly to the tumor within a patient’s own expanded immune cells, where they replicate and kill millions of cancer cells to debulk large tumors
  • Multi-mechanistic; application in multiple indications
  • Durable immune response prevents recurrence, and is potentially curative
  • Compelling animal data presented and published to support pursuit of development in humans

Our Unique Approach


The Scientific Foundation:


Current cancer therapies, including immunotherapies, have several major shortcomings. We address these by combining activated cytokine-induced killer cells (CIK) and an oncolytic virus that have been thoroughly tested in humans with excellent safety profiles but which if taken as individual therapies have limited efficacy. When combined, the two agents work synergistically to find and kill cancer cells, creating a powerful, next-generation cancer immunotherapy. Importantly, this combination therapy specifically targets solid and liquid tumors, attacking them on multiple fronts by releasing the oncolytic virus from an expanded/enriched population of CIK cells that have the ability to specifically traffic to and bind to tumor cells. The benefits of this approach include:


  • The compound acts as both a protector and carrier, activating the patient’s immune cells and enabling them to deliver a cancer-killing virus payload
  • Eradicates malignant cells and creates a long-term (durable) immune response that prevents new cancer growth (relapse or recurrence)
  • High effector-to-target ratio (1 million:1) allows for the debulking of large tumors; kills metastatic tumors
  • Can be made safely from the patient’s own CIK cells or from donor cells
  • Donor cells are not rejected by host, so repeat treatments are possible, if needed

Conclusion: CRX100 is both precise and systemic – It targets tumor cells and avoids healthy cells, and it has the ability to reach tumors all over the body. This means the compound holds promise for metastatic disease treatment with limited toxicity. Because our therapy uses a patient’s own immune cells, expanded and activated outside the body, a patient does not have to undergo depletion of their circulating cells by a specific drug or receive highly toxic cytokines during treatment, which may increase safety.

Board of Directors

Chairman, Board of Directors


Catherine Sohn is a pharmacist, global biopharmaceutical executive, Adjunct Professor and a Certified Licensing Professional (CLP). Dr. Sohn has deep industry knowledge from a 30-year career in the U.S. and global pharmaceutical industry, and a reputation as a strategic thinker with the ability to drive a strong interface between research and development and marketing. She was named “Distinguished Alumnus” by the University of California San Francisco (2000) and “Woman of the Year” by the Healthcare Businesswomen’s Association (2003), has received the Licensing Executive Society’s “Frank Barnes Mentoring Award” (2009), and the Healthcare Businesswomen’s Association Euro-Excellence Award (2012).


In 2016, Dr. Sohn was recognized as one of the PharmaVoice 100 most inspiring people in the life science industry.  Her areas of expertise include domestic and global business development, strategy and product marketing/launch execution across vaccines, pharmaceutical products and consumer healthcare brands, having led the launches of the U.S. Vaccine Business and a $1 billion CNS pharmaceutical product at SmithKline Beecham (now GlaxoSmithKline). From 1998 to 2010, Dr. Sohn was Senior Vice President for Worldwide Business Development for GlaxoSmithKline’s $6 billion Consumer Healthcare division, where she served on the Global Executive Committee and led numerous U.S., global, European and Japanese transactions and integrations. In the pharmaceutical division, from 1994 to 1998, she was Vice President, Worldwide Strategic Product Development at SmithKline Beecham for the Cardiovascular, Pulmonary, and Metabolic Therapeutic Areas, with responsibility for product strategy, valuation and strategic commercial leadership for all assets from Phase 1 through life cycle management. Dr. Sohn has a strong technical background, having begun her career in 1982 in anti-infective medical affairs at SmithKline & French.


Dr. Sohn received a Doctor of Pharmacy (Pharm. D.) degree from the University of California San Francisco, as well as a Certificate of Professional Development from The Wharton School at the University of Pennsylvania. She is a Board Leadership Fellow of the National Association of Corporate Directors (NACD), and is a Certified Licensing Professional.


Dr. Sohn is an Independent Director on the Board of Directors of Jazz Pharmaceuticals plc (Nasdaq: JAZZ), Rubius Therapeutics (Nasdaq: RUBY), Axcella Health (Nasdaq: AXLA) and Landec Corporation (Nasdaq: LNDC), all publicly-traded life science companies.

Chief Executive Officer, Director and Co-Founder


Pamela Contag, Ph.D., has a career as a biopharmaceutical entrepreneur, researcher and senior executive that spans more than 25 years.  Dr. Contag co-founded BioEclipse Therapeutics™, initially named ConcentRX, raising seed funding and licensing key patents from Stanford University with a mission to deliver transformative, safe and precise therapies for resistant and recurrent cancers regarded as virtually untreatable. As CEO of the company, she was named by Goldman Sachs as one of the 100 Most Intriguing Entrepreneurs of 2018, and in 2019, she successfully led BioEclipse through the completion of its Series A financing. Previously, Dr. Contag served as a senior executive for several pioneering biomedical technology companies, including Cygnet Biofuels, Cobalt Technologies and Xenogen Corp., which she co-founded based on technology she developed during her post doctorate training. As CEO of Xenogen from 1995 to 2006, Dr. Contag led the company’s successful initial public offering, grew U.S. and international revenue and built a customer base that included many leading pharmaceutical companies.


In 2004, Xenogen was named one of the top 100 fastest growing companies by the San Francisco Times and received the Frost and Sullivan Technology Innovations award.  Dr. Contag was recognized as one of the “Top 25 Young Businesses” by Fortune Small Business in 2000, followed in 2001 and 2003 with the R&D 100 award for achievements in Physics.  Dr. Contag was also named one of the “Top 25 Women in Small Business” by Fortune magazine. She was also awarded the Northstar Award from Springboard Enterprises. While she served as CEO and Chairman of Cobalt Technologies, the company was named one of the top 20 cleantech companies. In 2011, Dr. Contag was awarded “Cleantech Innovator of the Year” award for technology developed at Cygnet Biofuels.


With more than 25 years of microbiology research experience, Dr. Contag is widely published in the field of Microbiology and Optical Imaging and has over 35 patents in Biotechnology. Dr. Contag received her Ph.D. in Microbiology from the University of Minnesota Medical School in 1989 studying Microbial Physiology and Genetics (for Alternative Fuels), and completed her postdoctoral training at Stanford University School of Medicine in 1993 specializing in “Host/Pathogen Interactions.”


Member, Board Directors


Gregory Schiffman is a CPA and an accomplished senior finance executive with more than 25 years of strategic and operational finance, treasury, and corporate development, manufacturing and logistics experience.  Mr. Schiffman has served as CFO at Lion Biotechnologies, Inc., which has since been renamed Iovance Biotherapeutics, Inc., and served as Executive Vice President and CFO at StemCells, Inc., Dendreon Corp. and Affymetrix.  Notably, during his tenure at Dendreon, the company secured marketing authorization from the FDA and the European Commission for the world’s first cell-based, autologous immunotherapy for prostate cancer. Prior to these roles, Mr. Schiffman was Vice President and Controller at Applied BioSystems where he managed global financial operations and headed up a variety of global assignments at Hewlett Packard, including international finance projects in Europe and Asia, and a U.S. manufacturing operation.  Mr. Schiffman received an M.B.A. from Northwestern University’s Kellogg School of Management and holds a bachelor’s degree in accounting from De Paul University.

Member, Board of Directors


Oliver Hopkinson joined BioEclipse’s Board of Directors in 2019 as a representative of Revelis Capital Group, a Colorado-based venture firm that invests across a range of disruptive, early-stage tech companies. Mr. Hopkinson co-founded Revelis in early 2017, and currently serves as its Managing Principal, overseeing all aspects of its investment operations. To date, Revelis has consummated Series Seed and Series A investments in the biotech, software and data/blockchain sectors. Mr. Hopkinson graduated with a B.S. in Economics from Duke University in 2016, and he is a J.D. candidate at University of Colorado Law School.

Member, Board of Directors


Mark Frohlich, M.D, is an experienced biotechnology executive and medical oncologist who has been involved in the development of cellular immunotherapies for cancer for 20 years. He previously served as Executive VP of Portfolio Strategy at Juno Therapeutics prior to its acquisition by Celgene, and as Executive VP of Research and Development and Chief Medical Officer of Dendreon Corporation, where he led the clinical team responsible for the approval of the first cellular immunotherapy in the U.S. and Europe (Provenge®). Dr. Frohlich graduated Summa Cum Laude from Yale College with a B.S. in Economics and Electrical Engineering, and earned an M.D. from Harvard Medical School.  He continued his training at UCSF, where he completed an internal medicine residency, served as Chief Medical Resident, and subsequently completed an oncology fellowship program.

Member, Board of Directors


Biao He, Ph.D., is a Partner at Tsingyuan Ventures, where he has led the firm’s biomedical investments since 2017. Before arriving at Tsingyuan, Dr. He was a Partner at TEEC Angel Fund from 2012 to 2017 where he led their biomedical investment portfolio. Dr. He is also a Co-Founder of ACCB Biotech and Pinpoint Genomics.  ACCB Biotech is one of the leading companies in the space of precision medicine for oncology in China. As a co-founder of Pinpoint Genomics, he led the development of the first lung cancer molecular prognostic test, prior to its acquisition by Life Technologies in 2012.  Dr. He was a Professor in the Department of Surgery at the Cancer Research Center at the University of California, San Francisco (UCSF).  He earned a Ph.D. in Molecular Genetics from the University of Virginia and received a bachelor’s degree and a master’s degree in Biochemistry from Tsinghua University in Beijing.

Member, Board of Directors


Mahmoud Mahmoudian, Ph.D., FRSC, is a biopharmaceutical industry veteran who brings more than 30 years of global R&D, venture, and business development expertise driving growth strategies that identify and develop next-generation innovations into cures for major diseases that transform patients' lives. Most recently, Dr. Mahmoudian served as Senior Vice President and Head of Global Oncology External Innovation Hub at Sumitomo Dainippon Pharma Oncology (Sumitomo Oncology), where he led biotechnology investments, venture creation, company building, and expedited the discovery, incubation and regulatory approval of cell therapies, oncolytic viruses and other novel therapeutic technologies. Dr. Mahmoudian raised $70 million in capital to build academic and venture hubs. He also established oncology research alliances with Columbia University, the Wistar Institute, Harvard University, and the Dana-Farber Cancer Institute, and scouted venture capital investment opportunities that led to Sumitomo Oncology’s investment in the MPM Oncology Innovations Fund.


Dr. Mahmoudian previously served as Vice President, Head of Innovative Medicines at Ferring, Chief Innovation Officer and Chair of Executive Committee for Growth at Rohm & Haas (acquired by Dow) and Chief Biotechnology Officer at Eastman. At Merck and GlaxoSmithKline, he led global drug development teams with eight FDA approvals and product launches responsible for $15B in annual sales. Dr. Mahmoudian earned his Doctorate and Master of Science in Biotechnology from the Imperial College of Science, Technology and Medicine in London, UK. He is a Fellow of the Royal Society of Chemistry and an Executive in Residence at Columbia and Princeton universities.